M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy PharmaphorumAbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.Immunology & InflammationRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaphorum AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its ‘mega-blockbuster’ immunology pipeline. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly bets up to $800M for BioArctic’s brain delivery techNext: Pfizer drug acquired in Seagen deal disappoints in lung cancer study Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
